You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency

    SBC: COURAGE THERAPEUTICS INC            Topic: 102

    The melanocortin peptide therapeutic setmelanotide, (ImcivreeTM), is highly effective in the treatment of the rare obesity syndromes, POMC and leptin receptor deficiency. However, the drug is ineffective for the most common syndromic obesity, melanocortin-4 receptor (MC4R) deficiency (MC4R haploinsufficiency), found at a prevalence greater than 1/1000 individuals. Further, the drug is ineffective ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Making Connections Thru Music: A Group Music Therapy-Based Intervention for Persons with Dementia

    SBC: HOPEFUL AGING LLC            Topic: NIA

    PROJECT SUMMARY/ABSTRACTHealthcare systems around the world, including within the United States, have long-established shortages of trained caregivers (WHO, 2016; Jones, Liu, Murfield, andamp; Moyle, 2020). The American Health Care Association (2019) states that “the health care system has experienced a shortage of trained caregivers for critical roles for some time.” This scarcity directly im ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Targeting cadherin-11 in pancreatic cancer

    SBC: Diviner Therapeutics LLC            Topic: 102

    Pancreatic cancer is soon to be the second leading cause of cancer-related death with an overall median survival of 8 - 11 months. For 70% of patients, systemic chemotherapy is the only option and this mainly relieves the symptoms and/or slightly extends survival, rather than cures the patients. One of the hallmarks of PDAC is extensive fibrosis that comprises up to 80% of the tumor. Cancer-associ ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Continuous Photoacoustic Monitoring of Neonatal Stroke in Intensive Care Unit

    SBC: BRIMROSE TECHNOLOGY CORP            Topic: NIBIB

    PROJECT SUMMARY/ABSTRACT Neonatal encephalopathy can arise from fetal hypoxia-ischemia during labor, chronic uteroplacental inflammation, and large cerebral artery embolization primarily arising from dislodgement of a placental thrombus. Because of overlapping clinical presentation, differential diagnosis is often delayed until seizures develop and MRI can be safely performed, a time at which most ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Broadly Accessible Technologies for Single-cell Joint Analysis of Transcriptome and Epigenome

    SBC: EPIGENOME TECHNOLOGIES, INC            Topic: 101

    AbstractHistone modifications carry rich information of cellular memory and gene regulatory mechanisms. Single cell analysis of histone modification in conjunction with transcriptome could recover this critical layer of cell identity and help to dissect the cellular and molecular composition of complex tissues such as the brain. We recently developed an ultra-high throughput single cell multi-omic ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. AIDen: An AI-empowered detection and diagnosis system for jaw lesions using CBCT

    SBC: MS Technologies Corporation            Topic: NIDCR

    Dental CBCT is a 3D imaging modality widely adopted to help dentists detect and diagnose jaw lesions. Due to minimum information loss (compared to conventional 2D radiography) and low radiation exposure (compared to conventional CT), it has become the “go-to” radiographic technique in various dental fields. Gaps: Accompanying the clear benefits of dental CBCT is an overwhelming amount of 3D da ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Next generation anti-cancer drugdelivering cement for bone metastasis patients

    SBC: CURER INC            Topic: 102

    Abstract Our mission is to develop an innovative anti-cancer drug delivering bone cement for bone metastasis patients, which can be injected into metastasis-caused bone degeneration sites in a minimally invasive manner, to regress cancer, regenerate bone, and stop the pain. Metastasis is the main cause of cancer death. Bone is one of the most frequent cancer metastatic sites. About 350,000 America ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. An automated system to differentiate Kawasaki disease from febrile illness with real life clinical datasets in New York City

    SBC: HBI SOLUTIONS INC.            Topic: 100

    ABSTRACT – Kawasaki disease (KD) is the most common cause of acquired heart disease in children. Treatment with intravenous immunoglobulin (IVIG) reduces the incidence of coronary aneurysms and risk of long-term cardiovascular complications. IVIG is recommended to be given within 10 days of illness; however only 4.7% receive the correct diagnosis at the first medical visit. Timely and accurately ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting a non-opioid signaling pathway to reverse opioid-induced respiratory depression

    SBC: Olfa Thera, Inc.            Topic: NIDA

    Project Summary/AbstractThe opioid epidemic is a growing public health crisis with dramatic increase in overdose deaths caused by potent opioids like fentanyl. Currently, the standard treatment for opioid-induced respiratory depression is naloxone, a µ-opioid receptor antagonist. However, naloxone is less effective against potent synthetic opioids like fentanyl and induces withdrawal in chronic o ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Development of liver homing PAR2 pepducins for the treatment of HepatocellularCarcinoma

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NCI

    Hepatocellular carcinoma (HCC) has become the second leading cause of cancer-related death in the world, with a 72% mortality rate in the US. The rise in incidence of HCC is due to a steady increase in the major risk factors of liver fibrosis, cirrhosis, and hepatitis B/C, with limited efficacy conferred by existing treatments at advanced stages of the disease. Systemic therapy with tyrosine kinas ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government